Cash Flow Statement (Annual)

HEI / HEICO Corp. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Profit Loss 72,355 95,453 106,675 124,561 138,772 153,564 176,150 207,660
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation Depletion And Amortization 17,597 18,543 30,656 36,790 47,757 47,907 60,277 64,823
    Defined Contribution Plan Employer Discretionary Contribution Amount - - 982 2,985 6,302 6,125 7,020 7,768
    Stock Option Plan Expense 1,353 2,647 3,948 5,117 6,426 6,048 6,434 7,415
    Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 - - - - 28,126 - - -
    Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 - -1,150 119 -1,640 -28,126 293 3,063 1,100
    Foreign Currency Transaction Loss Before Tax - - - - - - 13 -
    Foreign Currency Transaction Gain Before Tax - - - 0 0 3,704 - -
    Deferred Income Tax Expense Benefit 1,817 29 -2,834 -5,785 -16,745 -7,080 -9,194 -11,096
    Increase Decrease In Operating Capital
      Increase Decrease In Receivables -10,684 5,327 5,782 16,585 -6,999 22,572 15,955 -2,846
      Increase Decrease In Inventories 6,359 9,405 7,484 14,877 -126 10,187 14,421 21,204
      Increase Decrease In Prepaid Deferred Expense And Other Assets 549 343 1,072 4,918 -8,033 -1,433 2,356 -134
      Increase Decrease In Accounts Payable 125 7,257 4,269 -23 2,511 3,169 4,074 6,386
      Increase Decrease In Accrued Liabilities 11,474 10,425 5,182 12,766 -3,090 -883 35,279 1,794
      Increase Decrease In Accrued Income Taxes Payable -1,196 1,516 1,759 -7,273 1,462 373 1,443 6,071
    Other Noncash Income Expense 248 471 -1,113 -653 - - - -
  Net Cash Provided By Used In Operating Activities 101,717 125,518 - - - 172,863 249,184 274,885
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Businesses Net Of Cash Acquired 39,061 94,655 197,285 222,638 8,737 166,784 263,811 418,265
  Payments To Acquire Property Plant And Equipment 8,877 9,446 15,262 18,328 16,410 18,249 30,863 25,998
  Payments For Proceeds From Other Investing Activities 325 -201 161 342 40 973 2,942 552
  Net Cash Provided By Used In Investing Activities -48,263 -103,900 - - - -186,006 -297,616 -444,815
Net Cash Provided By Used In Financing Activities
  Proceeds From Long Term Lines Of Credit 37,000 72,000 191,000 372,000 112,000 173,696 260,000 404,000
  Repayments Of Long Term Lines Of Credit 78,000 50,000 100,000 126,000 159,000 132,000 170,000 190,877
  Common Stock Issued Repurchased And Retired Related To Stock Option Exercises 681 14,298 307 2,364 273 5 - -
  Payments Of Dividends Common Stock 3,546 4,494 5,689 120,361 31,215 9,343 10,724 12,807
  Payments Of Dividends Minority Interest 10,360 14,893 9,090 7,579 79,212 9,699 19,017 18,401
  Payments Of Debt Issuance Costs 0 0 3,028 570 767 0 0 270
  Payments To Minority Shareholders - 0 0 601 - - - -
  Paymentof Contingent Consideration - - - - - - 6,329 7,039
  Proceeds From Stock Options Exercised 1,815 2,167 833 463 708 3,673 5,924 5,659
  Proceeds From Payments For Other Financing Activities -294 -256 214 -296 -1,206 -393 -364 -545
  Net Cash Provided By Used In Financing Activities -54,192 -10,669 - - - 27,336 56,772 175,872
Effect Of Exchange Rate On Cash And Cash Equivalents 114 8 -353 312 -657 -819 1,012 3,169
Cash And Cash Equivalents Period Increase Decrease -624 10,957 3,951 -5,952 4,730 13,374 9,352 9,111
Cash And Cash Equivalents At Carrying Value - - - 15,499 20,229 33,603 42,955 52,066

Peers - Aircraft Engines and Engine Parts (3724)

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 422806109